Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer
Stopped Enrolment suspended to further assess supplementary non-clinical study data.
Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
Interventions
- DRUG: Pidnarulex
- DRUG: Talazoparib
Sponsor
Peter MacCallum Cancer Centre, Australia